Codexis Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis or view top-rated stocks.

Wall Street analysts have given Codexis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Codexis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Codexis.

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.10. The biotechnology company had revenue of $25.45 million for the quarter, compared to analysts' expectations of $18.04 million. Codexis had a negative net margin of 28.16% and a negative trailing twelve-month return on equity of 15.90%.
View Codexis' earnings history.

Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CDXS stock has increased by 148.4% and is now trading at $25.14.
View which stocks have been most impacted by COVID-19.

Codexis issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $98 million-$103 million, compared to the consensus revenue estimate of $88.50 million.

4 brokers have issued 12 month target prices for Codexis' shares. Their forecasts range from $28.00 to $34.00. On average, they anticipate Codexis' stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price.
View analysts' price targets for Codexis or view top-rated stocks among Wall Street analysts.

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of CDXS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.35%), Baillie Gifford & Co. (10.32%), BlackRock Inc. (8.21%), Nantahala Capital Management LLC (5.97%), Vanguard Group Inc. (4.93%) and William Blair Investment Management LLC (3.63%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Nantahala Capital Management LLC, Nuveen Asset Management LLC, JPMorgan Chase & Co., Opaleye Management Inc., Bank of New York Mellon Corp, Deutsche Bank AG, and Morgan Stanley. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis or view top insider-selling stocks.

CDXS stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., ARK Investment Management LLC, Pier Capital LLC, Dimensional Fund Advisors LP, BlackRock Inc., American Century Companies Inc., AIA Group Ltd, and First Trust Advisors LP.
View insider buying and selling activity for Codexis or or view top insider-buying stocks.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDXS stock can currently be purchased for approximately $25.14.

Codexis has a market capitalization of $1.63 billion and generates $69.06 million in revenue each year. The biotechnology company earns $-24,010,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

Codexis employs 181 workers across the globe.

The official website for Codexis is www.codexis.com.

Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at (650) 421-8100 or via email at [email protected].